CAR T-Cell Therapy Pushes Grandmother’s Multiple Myeloma Into Long Remission

As head of a family that includes seven children and 12 grandchildren, Susan Voigt says she is used to putting other people first. When it comes to trailblazing multiple myeloma treatment, however, she is proudly out in front. A longtime Vermont resident, Voigt, 69, was the first person from her state to receive CAR T-cell … Read more

New Drug Regimens Show Promise in Early and Late Myeloma

Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations — newly diagnosed, transplant eligible patients, and individuals whose disease has progressed following several lines of therapy. In one trial, the phase 2 GRIFFIN study showed … Read more

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results … Read more

Cancer Patient Faces Multiple Diagnoses with the Strength of a Warrior

One bout of cancer is enough to contend with, but since 2014 Mary Johnson has had to cope with four different cancers and related conditions. Despite these tests of her physical and emotional strength, Johnson is doing well today after treatment at Dana-Farber. “Coming to Dana-Farber gave me confidence because they supported me, and I … Read more

Approval of Myeloma Drug Improves Patients’ Prospects

Five years into his treatment for multiple myeloma, Mark Young was attending a Dana-Farber conference to learn about the latest research in the disease when his oncologist — Paul Richardson, MD, clinical program leader and director of clinical research at the Institute’s Jerome Lipper Multiple Myeloma Center — came running up with some timely news. … Read more

Multiple Myeloma Fails to Keep Jimmy Cefalo Out of Action

Many sports stars have helped support research and care at Dana-Farber by appearing on the WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance Foundation, but few have done so quite like pro football wide receiver-turned-broadcaster Jimmy Cefalo. When Cefalo was interviewed on-air during the August 2019 event at Fenway Park, he used the opportunity to share some … Read more

New Drug Benefits Patients With Myeloma Who Are Resistant to All Therapies

Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of currently available therapies, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. A clinical trial found that 26.2 percent of such patients responded with significant shrinkage … Read more

Study Finds Advantage for African Americans with Multiple Myeloma

In a surprising rebuttal of previous findings, a new study shows that African Americans with multiple myeloma have an overall higher survival rate than Caucasians with the disease when all patients have equal access to cutting-edge therapies. The results raise questions about the biology of this type of cancer. Multiple myeloma, a cancer that arises … Read more

After Cancer Treatment, Father and Daughter Come Out With an Even Stronger Bond

As father and daughter, there are many things Dennis Gorden and Becky Nutley share: a contagious smile, the instinct to help others, and a commitment to family, to name a few. But one thing they never imagined they would have in common was a cancer diagnosis. In 2014, routine blood work revealed that Becky Nutley, … Read more

Myeloma Study Makes the Case for a New Standard for Predicting Long-Term Outcome

As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper … Read more

Immunotherapies Producing Dramatic Results in Multiple Myeloma

Advances against multiple myeloma have come at an especially rapid pace, with 10 new therapies approved in just the last 10 years. As a group, their impact “is greater than anything we’ve seen in myeloma,” says Nikhil Munshi, MD, director of Basic and Correlative Science at Dana-Farber’s Jerome Lipper Center for Multiple Myeloma.